Ovarian cancer is hard to detect, but new and better ...
WEBSep 6, 2022 · Advanced-stage ovarian cancer has a higher rate of recurrence, and Dr. Butler says early detection is important to improve survival.
Promising New Blood Test Accurately Detects Ovarian Cancer
WEBOct 18, 2023 · The new blood test was 91% accurate at detecting high-grade serous ovarian carcinoma (HGSOC), which is the most common type of ovarian cancer, according to results published this month in the...
Mirvetuximab Soravtansine-Gynx Approved for Ovarian Cancer
WEBApr 24, 2024 · Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option.
Ovarian cancer: New treatments and research - Mayo Clinic ...
WEBMay 1, 2024 · If you've been diagnosed with ovarian cancer, he wants you to know there is hope. Here's why: New targeted therapies are improving survival. Surgery and chemotherapy are no longer the only options for ovarian cancer treatment. Targeted therapies use drugs to target and attack cancer cells.
A Game-Changer for Ovarian Cancer | Johns Hopkins Medicine
WEBJun 6, 2024 · Ovarian cancer is a notoriously difficult group of diseases to diagnose and treat. There is no effective screening method — most people have widely metastatic cancer when they start showing symptoms, and most patients die within five years. A new approach offers some hope in preventing this disease.
FDA Approves New Treatment Option for Ovarian Cancer
WEBNov 17, 2022 · On November 14, the Food and Drug Administration (FDA) granted accelerated approval of Elahere (mirvetuximab soravtansine), a novel antibody-drug conjugate for people with previously treated ovarian, fallopian tube or primary peritoneal cancer who no longer respond to platinum chemotherapy.
Antibody drug conjugates make strides in ovarian cancer with ...
WEBFeb 12, 2024 · The UCLA Health women’s cancer research team in OBGYN played a pivotal role in a clinical trial that led to the FDA granting accelerated approval of the first antibody drug conjugate for the treatment of platinum-resistant ovarian cancer.
Skip to content